We therefore utilized CRISPR knockin technology to create a transgenic luminal bladder cancer cell line engineered to express GFP and PPARG proportionally, so that fluorescence could be used as a readout to identify endogenous regulators of PPARG expression. The gene discussed is PPARG; the disease is urinary bladder carcinoma.